Updated:
Fine Structure Ventures
Fine Structure Ventures focuses on early stage investments in disruptive scientific and technological innovation. The firm backs teams deploying...
Overview
Fine Structure Ventures focuses on early stage investments in disruptive scientific and technological innovation. The firm backs teams deploying revolutionary technologies, with over 300 active patents across its portfolio. It has board representation at over 80% of portfolio companies and invests from pre-seed to pre-IPO. Portfolio companies have collectively raised over two billion dollars.
General information
Firm type
Venture Capital
Year founded
2020
Location
Region
North America
Country
United States
City
Cambridge
Corporate office
1 Main Street, 13th Floor, Cambridge, MA 02142, United States
Principals
Jennifer Uhrig
Investment Team
Shyam Kamadolli
Investment Team
David Needell, PhD
Investment Team
Amrit Jalan, PhD
Investment Team
Tobias Egle, PhD
Investment Team
Dionis Minev, PhD
Investment Team
Crissy Derome
Operations
Sector focus
Frequently asked questions
Who runs investment decisions at Fine Structure Ventures?
Investment decisions appear to be made by a small, flat team. Jennifer Uhrig, Shyam Kamadolli and David Needell are named across the largest number of disclosed portfolio positions, spanning Fund I and Fund II companies in fusion energy, steel decarbonization, satellite relays, space launch and edge AI hardware. The firm does not designate a managing partner or CEO in its public materials and emphasizes a collaborative, specialist decision-making structure.
Does Fine Structure Ventures participate in fund commitments or only direct deals?
Available evidence points to direct equity only. The firm lists only individual portfolio companies on its website, refers to board representation at over 80% of holdings, and discloses no fund-of-funds, SPV or co-investment-vehicle activity. There is no mention of GP stakes, LP interests in other venture firms, or a separate allocation to outside managers.
What investment stages does Fine Structure Ventures typically target?
The firm self-identifies as covering the full lifecycle, from pre-seed to pre-IPO, but its disclosed activity tilts toward early-stage science bets. Fund I (vintage years 2020–2021) includes pre-product and early-commercialization companies such as Mainspring Energy, Osmoses and Nitricity. Fund II (2022–2025) extends the same deep-tech theme to slightly later-stage platform companies like Aalo Atomics and pH7 Technologies.
Which sectors does Fine Structure Ventures explicitly avoid?
The firm’s five published categories — aerospace, biology, computing, energy, and materials — function as a negative screen for everything outside them. There are no disclosed portfolio companies in enterprise software, fintech, consumer internet, entertainment, or business services. The firm does not list healthcare services, diagnostics or therapeutics as categories, though biology holdings (Constructive Bio, Nulixir, Debut Biotech) touch industrial biotech and food tech rather than pharma.
What is Fine Structure Ventures’ known posture on co-investments alongside external GPs?
The firm co-invests with breakthrough-energy backers and government-linked entities — Commonwealth Fusion Systems counts leading clean-energy investors, and Aalo Atomics secured approval to build at Idaho National Laboratory — but Fine Structure Ventures does not describe itself as a co-investment specialist. It has not disclosed a formal LP co-investment program or club-deal infrastructure common among multi-family-office platforms.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: